Genmab — Januar 2019
-
resten af pipen er meeeeeget langt fra lige så meget værd som dara. Fordi den er så early og usikkerhederne dermed er mange. Men jeg tror sukker framer den meget godt mht jans frustration. At alt det de internt arbejder på dermed ikke rigtigt bliver "anerkendt". Men velkommen til Biotech branchen. Sådan har det ALLE dage været
-
-
Dr. Rifkin on Split Dosing of Daratumumab in Myeloma https://www.youtube.com/watch?v=8j5l5SSj4Gs
-
Celgene raised Revlimid price by 3.5 percent https://www.bloomberg.com/news/articles/2019-01-04/celgene-boosted-price-of-its-top-cancer-drug-on-day-of-mega-deal
-
-
Ditto her i Regstrup.
-
Ret vild med denne overskrift: http://www.proinvestor.com/investornyt/585264/panikkdrevet-ettersporsel-pa-borsene-i-new-york
-
Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation - A Network Meta-analysis http://www.haematologica.org/content/early/2019/01/02/haematol.2018.206912
-
Article in Blood Cancer Journal: "Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provices evidence for shared aetiology". Spændende om det på sigt kan føre til noget positivt for DARA, der har et par studier kombineret med Ibrutinib. https://www.nature.com/articles/s41408-018-0162-8
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind